FDA Response to COVID Gives Insights for Regulatory Future of LDTs
Certain temporary deviations in FDA policy in response to the COVID-19 pandemic may offer a blueprint for regulatory oversight of LDTs.
Read MorePosted by Chris Wolski | Sep 17, 2021 | Compliance |
Certain temporary deviations in FDA policy in response to the COVID-19 pandemic may offer a blueprint for regulatory oversight of LDTs.
Read MorePosted by Chris Wolski | Sep 16, 2021 | Disease States |
Cairn Diagnostics has announced that the U.S. FDA has expanded the approval of the company’s 13C-Spirulina GEBT to now include “at home” administration.
Read MorePosted by Chris Wolski | Sep 15, 2021 | Benches |
Laboratory equipment is a vital for any healthcare enterprise and maximizing high-performance workstations is fundamental to laboratory workflow success.
Read MorePosted by Chris Wolski | Sep 10, 2021 | Covid 19 |
Carnival Corporation has announced a new initiative making pre-board testing more convenient and accessible for its guests through Quest Diagnostics.
Read MorePosted by Chris Wolski | Sep 10, 2021 | Covid 19 |
President Joseph R. Biden announced that he will be enacting broad mandates requiring most of the...
Read More